Selection criteria for early breast cancer patients in the DBCG proton trial - The randomised phase III trial strategy

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Selection criteria for early breast cancer patients in the DBCG proton trial - The randomised phase III trial strategy. / Stick, Line Bjerregaard; Lorenzen, Ebbe Laugaard; Yates, Esben Svitzer; Anandadas, Carmel; Andersen, Karen; Aristei, Cynthia; Byrne, Orla; Hol, Sandra; Jensen, Ingelise; Kirby, Anna M.; Kirova, Youlia M.; Marrazzo, Livia; Matias-Perez, Angela; Nielsen, Mette Marie Bruun; Nissen, Henrik Dahl; Oliveros, Sileida; Verhoeven, Karolien; Vikstrom, Johan; Offersen, Birgitte Vrou.

In: Clinical and Translational Radiation Oncology, Vol. 27, 03.2021, p. 126-131.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Stick, LB, Lorenzen, EL, Yates, ES, Anandadas, C, Andersen, K, Aristei, C, Byrne, O, Hol, S, Jensen, I, Kirby, AM, Kirova, YM, Marrazzo, L, Matias-Perez, A, Nielsen, MMB, Nissen, HD, Oliveros, S, Verhoeven, K, Vikstrom, J & Offersen, BV 2021, 'Selection criteria for early breast cancer patients in the DBCG proton trial - The randomised phase III trial strategy', Clinical and Translational Radiation Oncology, vol. 27, pp. 126-131. https://doi.org/10.1016/j.ctro.2021.01.012

APA

Stick, L. B., Lorenzen, E. L., Yates, E. S., Anandadas, C., Andersen, K., Aristei, C., Byrne, O., Hol, S., Jensen, I., Kirby, A. M., Kirova, Y. M., Marrazzo, L., Matias-Perez, A., Nielsen, M. M. B., Nissen, H. D., Oliveros, S., Verhoeven, K., Vikstrom, J., & Offersen, B. V. (2021). Selection criteria for early breast cancer patients in the DBCG proton trial - The randomised phase III trial strategy. Clinical and Translational Radiation Oncology, 27, 126-131. https://doi.org/10.1016/j.ctro.2021.01.012

Vancouver

Stick LB, Lorenzen EL, Yates ES, Anandadas C, Andersen K, Aristei C et al. Selection criteria for early breast cancer patients in the DBCG proton trial - The randomised phase III trial strategy. Clinical and Translational Radiation Oncology. 2021 Mar;27:126-131. https://doi.org/10.1016/j.ctro.2021.01.012

Author

Stick, Line Bjerregaard ; Lorenzen, Ebbe Laugaard ; Yates, Esben Svitzer ; Anandadas, Carmel ; Andersen, Karen ; Aristei, Cynthia ; Byrne, Orla ; Hol, Sandra ; Jensen, Ingelise ; Kirby, Anna M. ; Kirova, Youlia M. ; Marrazzo, Livia ; Matias-Perez, Angela ; Nielsen, Mette Marie Bruun ; Nissen, Henrik Dahl ; Oliveros, Sileida ; Verhoeven, Karolien ; Vikstrom, Johan ; Offersen, Birgitte Vrou. / Selection criteria for early breast cancer patients in the DBCG proton trial - The randomised phase III trial strategy. In: Clinical and Translational Radiation Oncology. 2021 ; Vol. 27. pp. 126-131.

Bibtex

@article{c1d836fe12c44acdb8eb343b72694ba9,
title = "Selection criteria for early breast cancer patients in the DBCG proton trial - The randomised phase III trial strategy",
abstract = "Background and purpose: Adjuvant radiotherapy of internal mammary nodes (IMN) improves survival in high-risk early breast cancer patients but inevitably leads to more dose to heart and lung. Target coverage is often compromised to meet heart/lung dose constraints. We estimate heart and lung dose when target coverage is not compromised in consecutive patients. These estimates are used to guide the choice of selection criteria for the randomised Danish Breast Cancer Group (DBCG) Proton Trial.Materials and methods: 179 breast cancer patients already treated with loco-regional IMN radiotherapy from 18 European departments were included. If the clinically delivered treatment plan did not comply with defined target coverage requirements, the plan was modified retrospectively until sufficient coverage was reached. The choice of selection criteria was based on the estimated number of eligible patients for different heart and lung dose thresholds in combination with proton therapy capacity limitations and dose-response relationships for heart and lung.Results: Median mean heart dose was 3.0 Gy (range, 1.1-8.2 Gy) for left-sided and 1.4 Gy (0.4-11.5 Gy) for right-sided treatment plans. Median V17Gy/V20Gy (hypofractionated/normofractionated plans) for ipsilateral lung was 31% (9-57%). The DBCG Radiotherapy Committee chose mean heart dose > 4 Gy and/or lung V17Gy/V20Gy >= 37% as thresholds for inclusion in the randomised trial. Using thesethresholds, we estimate that 22% of patients requiring loco-regional IMN radiotherapy will be eligible for the trial.Conclusion: The patient selection criteria for the DBCG Proton Trial are mean heart dose >= 4 Gy and/or lung V17Gy/V20Gy >= 37%. (C) 2021 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.",
keywords = "Patient selection, Breast cancer, Proton therapy, Heart and lung exposure",
author = "Stick, {Line Bjerregaard} and Lorenzen, {Ebbe Laugaard} and Yates, {Esben Svitzer} and Carmel Anandadas and Karen Andersen and Cynthia Aristei and Orla Byrne and Sandra Hol and Ingelise Jensen and Kirby, {Anna M.} and Kirova, {Youlia M.} and Livia Marrazzo and Angela Matias-Perez and Nielsen, {Mette Marie Bruun} and Nissen, {Henrik Dahl} and Sileida Oliveros and Karolien Verhoeven and Johan Vikstrom and Offersen, {Birgitte Vrou}",
year = "2021",
month = mar,
doi = "10.1016/j.ctro.2021.01.012",
language = "English",
volume = "27",
pages = "126--131",
journal = "Clinical and Translational Radiation Oncology",
issn = "2405-6308",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Selection criteria for early breast cancer patients in the DBCG proton trial - The randomised phase III trial strategy

AU - Stick, Line Bjerregaard

AU - Lorenzen, Ebbe Laugaard

AU - Yates, Esben Svitzer

AU - Anandadas, Carmel

AU - Andersen, Karen

AU - Aristei, Cynthia

AU - Byrne, Orla

AU - Hol, Sandra

AU - Jensen, Ingelise

AU - Kirby, Anna M.

AU - Kirova, Youlia M.

AU - Marrazzo, Livia

AU - Matias-Perez, Angela

AU - Nielsen, Mette Marie Bruun

AU - Nissen, Henrik Dahl

AU - Oliveros, Sileida

AU - Verhoeven, Karolien

AU - Vikstrom, Johan

AU - Offersen, Birgitte Vrou

PY - 2021/3

Y1 - 2021/3

N2 - Background and purpose: Adjuvant radiotherapy of internal mammary nodes (IMN) improves survival in high-risk early breast cancer patients but inevitably leads to more dose to heart and lung. Target coverage is often compromised to meet heart/lung dose constraints. We estimate heart and lung dose when target coverage is not compromised in consecutive patients. These estimates are used to guide the choice of selection criteria for the randomised Danish Breast Cancer Group (DBCG) Proton Trial.Materials and methods: 179 breast cancer patients already treated with loco-regional IMN radiotherapy from 18 European departments were included. If the clinically delivered treatment plan did not comply with defined target coverage requirements, the plan was modified retrospectively until sufficient coverage was reached. The choice of selection criteria was based on the estimated number of eligible patients for different heart and lung dose thresholds in combination with proton therapy capacity limitations and dose-response relationships for heart and lung.Results: Median mean heart dose was 3.0 Gy (range, 1.1-8.2 Gy) for left-sided and 1.4 Gy (0.4-11.5 Gy) for right-sided treatment plans. Median V17Gy/V20Gy (hypofractionated/normofractionated plans) for ipsilateral lung was 31% (9-57%). The DBCG Radiotherapy Committee chose mean heart dose > 4 Gy and/or lung V17Gy/V20Gy >= 37% as thresholds for inclusion in the randomised trial. Using thesethresholds, we estimate that 22% of patients requiring loco-regional IMN radiotherapy will be eligible for the trial.Conclusion: The patient selection criteria for the DBCG Proton Trial are mean heart dose >= 4 Gy and/or lung V17Gy/V20Gy >= 37%. (C) 2021 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.

AB - Background and purpose: Adjuvant radiotherapy of internal mammary nodes (IMN) improves survival in high-risk early breast cancer patients but inevitably leads to more dose to heart and lung. Target coverage is often compromised to meet heart/lung dose constraints. We estimate heart and lung dose when target coverage is not compromised in consecutive patients. These estimates are used to guide the choice of selection criteria for the randomised Danish Breast Cancer Group (DBCG) Proton Trial.Materials and methods: 179 breast cancer patients already treated with loco-regional IMN radiotherapy from 18 European departments were included. If the clinically delivered treatment plan did not comply with defined target coverage requirements, the plan was modified retrospectively until sufficient coverage was reached. The choice of selection criteria was based on the estimated number of eligible patients for different heart and lung dose thresholds in combination with proton therapy capacity limitations and dose-response relationships for heart and lung.Results: Median mean heart dose was 3.0 Gy (range, 1.1-8.2 Gy) for left-sided and 1.4 Gy (0.4-11.5 Gy) for right-sided treatment plans. Median V17Gy/V20Gy (hypofractionated/normofractionated plans) for ipsilateral lung was 31% (9-57%). The DBCG Radiotherapy Committee chose mean heart dose > 4 Gy and/or lung V17Gy/V20Gy >= 37% as thresholds for inclusion in the randomised trial. Using thesethresholds, we estimate that 22% of patients requiring loco-regional IMN radiotherapy will be eligible for the trial.Conclusion: The patient selection criteria for the DBCG Proton Trial are mean heart dose >= 4 Gy and/or lung V17Gy/V20Gy >= 37%. (C) 2021 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.

KW - Patient selection

KW - Breast cancer

KW - Proton therapy

KW - Heart and lung exposure

U2 - 10.1016/j.ctro.2021.01.012

DO - 10.1016/j.ctro.2021.01.012

M3 - Journal article

C2 - 33659716

VL - 27

SP - 126

EP - 131

JO - Clinical and Translational Radiation Oncology

JF - Clinical and Translational Radiation Oncology

SN - 2405-6308

ER -

ID: 260254788